Sign up
Pharma Capital

Phase II Peprostat study 'a major milestone' says Ergomed's Andrew Mackie

Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.


View full ERGO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.